Enhancing CRP Protein Detection with Monoclonal Antibodies: A Breakthrough in Inflammatory Disease Diagnostics
CRP is synthesized by the liver in response to several inflammatory cytokines and is a well-established biomarker of inflammation and infection. Elevated CRP levels are associated with several diseases, including inflammatory bowel disease, rheumatoid arthritis, cardiovascular disease, infection, and cancer. SYnAbs Monoclonal antibodies offer several advantages for CRP diagnosis in a precision medicine context.
Unravel the Epigenetic Code: Unlocking the Secrets of Histone Modifications with SYnAbs Specific Monoclonal Antibodies
How epigenetic alterations on histones are strong biomarkers of disease evolution and how to target these post-translational modifications effectively with SYnAbs higher specific mouse and rat monoclonal antibodies

Decoding Matrix Metalloproteinases (MMP): A Journey towards effective Therapeutic interventions
11. February 2023
Thanks to unique technologies to break immune tolerance, SYnAbs generate monoclonal antibodies to Matrix metalloproteinases (MMPs), extracellular proteinase enzymes involved in the degradation of the extracellular matrix.
Claudin and Occludin : potential of tetraspan transmembrane proteins of cell-cell tight junctions as antibody therapeutic targets
25. January 2023
SYnAbs generates R&D, surrogate and therapeutic monoclonal antibodies targeting occludin and claudin highly homologous transmembrane proteins

SYnAbs is awarded a major Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
New primary monoclonal antibodies · 25. November 2022
Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
Membrane Antibody Therapeutic Approach to Ion Channelopathies
SYnAbs' unique approach generating ultra-specific therapeutic monoclonals to ion channels and effectively treat channelopathies thanks to a unique antibody platform

SYnAbs launches unique anti-glucagon monoclonals
New primary monoclonal antibodies · 03. October 2022
SYnAbs monoclonals specific to glucagon without cross-reaction to GLP-1, Glicentin, Oxyntomodulin and Proglucagon, to diagnose diabetes and glucagonomas diseases
SYnAbs signs a research agreement with Domain Therapeutics to discover therapeutic antibodies on GPCRs
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications

G protein-coupled endothelin receptors and their natural and therapeutic ligands
From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins
Glutamate transporter : a brief history of excitatory amino acid transmembrane proteins
SYnAbs has developed R&D and therapeutic monoclonal antibodies against transporters and ion channel such as glutamate EAAT transmembrane targets thanks to peptide and syngeneic cell immunization strategies

Show more